Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors ; volume:13 ; number:1 ; day:9 ; month:6 ; year:2023 ; pages:1-9 ; date:12.2023
Scientific reports ; 13, Heft 1 (9.6.2023), 1-9, 12.2023
- Urheber
-
You, Weir-Chiang
Lee, Hsu-Dung
Pan, Hung-Chuan
Chen, Hung-Chieh
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-36290-2
- URN
-
urn:nbn:de:101:1-2023091909102908060642
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- You, Weir-Chiang
- Lee, Hsu-Dung
- Pan, Hung-Chuan
- Chen, Hung-Chieh
- SpringerLink (Online service)
Ähnliche Objekte (12)
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
Re-irradiation for recurrent glioblastoma: a pattern of care analysis
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Expert consensus on re-irradiation for recurrent glioma
Expert consensus on re-irradiation for recurrent glioma
Expert consensus on re-irradiation for recurrent glioma
Bevacizumab for patients with recurrent multifocal glioblastomas
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
Re-irradiation for recurrent glioblastoma: a pattern of care analysis
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Expert consensus on re-irradiation for recurrent glioma
Expert consensus on re-irradiation for recurrent glioma
Expert consensus on re-irradiation for recurrent glioma
Bevacizumab for patients with recurrent multifocal glioblastomas
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
Re-irradiation for recurrent glioblastoma: a pattern of care analysis
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Expert consensus on re-irradiation for recurrent glioma
Expert consensus on re-irradiation for recurrent glioma
Expert consensus on re-irradiation for recurrent glioma